Top

Published in:

01-09-2015 | Research Article

Genetic polymorphisms of the multidrug resistance 1 gene MDR1 and the risk of hepatocellular carcinoma

Authors: Zhi-Chao Wang, Long-Zi Liu, Xin-Yang Liu, Jin-Jing Hu, Yong-Na Wu, Jie-Yi Shi, Liu-Xiao Yang, Meng Duan, Xiao-Ying Wang, Jian Zhou, Jia Fan, Qiang Gao

Published in: Tumor Biology | Issue 9/2015

Abstract

A possible association between multiple drug resistance 1 gene (MDR1) polymorphisms and the risk of developing hepatocellular carcinoma (HCC) is currently under debate, and evidence from various epidemiological studies has yielded controversial results. To derive a more precise estimation of the association between MDR1 polymorphisms and HCC risk, the present meta-analysis was performed. A total of 8 studies containing 11 cohorts with 4407 cases and 4436 controls were included by systematic literature search of EMBASE, PubMed, Web of Science, and CNKI. All polymorphisms were classified as mutant/wild-type alleles. In particular, the variation type, functional impact, and protein domain location of the polymorphisms were assessed and used as stratified indicators. The pooled odds ratio (OR) with 95 % confidence interval (CI) was calculated to evaluate the association. Overall, our results suggested that the mutant alleles of the MDR1 gene were associated with a significantly increased risk for HCC under all genetic models (allelic model: OR = 1.28, 95 % CI = 1.20–1.36, P < 0.001; dominant model: OR = 1.27, 95 % CI = 1.16–1.38, P < 0.001; recessive model: OR = 1.59, 95 % CI = 1.36–1.85, P < 0.001). Furthermore, increased risks for HCC were also revealed in stratified analyses by ethnicity, sample size, and quality scores of cohorts as well as variation type, functional impact, and protein domain location of polymorphisms. In conclusion, the present meta-analysis suggested that the presence of MDR1 mutant alleles might be a risk factor for HCC.

Available only for authorised users

Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(9822):1245–55. doi:10.1016/S0140-6736(11)61347-0.CrossRefPubMed

Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29. doi:10.3322/caac.21208.CrossRefPubMed

El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557–76. doi:10.1053/j.gastro.2007.04.061.CrossRefPubMed

Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5(9):558–67. doi:10.1016/S1473-3099(05)70216-4.CrossRefPubMed

Tanaka M, Katayama F, Kato H, Tanaka H, Wang J, et al. Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. J Epidemiol. 2011;21(6):401–16.CrossRefPubMedPubMedCentral

Wang ZC, Gao Q, Shi JY, Yang LX, Zhou J, et al. Genetic polymorphism of the kinesin-like protein KIF1B gene and the risk of hepatocellular carcinoma. PLoS One. 2013;8(4):e62571. doi:10.1371/journal.pone.0062571.CrossRefPubMedPubMedCentral

Dragani TA. Risk of HCC: genetic heterogeneity and complex genetics. J Hepatol. 2010;52(2):252–7. doi:10.1016/j.jhep.2009.11.015.CrossRefPubMed

Jiang DK, Sun J, Cao G, Liu Y, Lin D, et al. Genetic variants in STAT4 and HLA-DQ genes confer risk of hepatitis B virus-related hepatocellular carcinoma. Nat Genet. 2013;45(1):72–5. doi:10.1038/ng.2483.CrossRefPubMed

Park EJ, Lee JH, Yu GY, He G, Ali SR, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell. 2010;140(2):197–208. doi:10.1016/j.cell.2009.12.052.CrossRefPubMedPubMedCentral

10.

Sun B, Karin M. Obesity, inflammation, and liver cancer. J Hepatol. 2012;56(3):704–13. doi:10.1016/j.jhep.2011.09.020.CrossRefPubMed

11.

Aleksandrova K, Boeing H, Nothlings U, Jenab M, Fedirko V, et al. Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer. Hepatology. 2014. doi:10.1002/hep.27016.PubMedCentral

12.

Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem. 2002;71:537–92. doi:10.1146/annurev.biochem.71.102301.093055.CrossRefPubMed

13.

Szakacs G, Varadi A, Ozvegy-Laczka C, Sarkadi B. The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov Today. 2008;13(9-10):379–93. doi:10.1016/j.drudis.2007.12.010.CrossRefPubMed

14.

Ros JE, Libbrecht L, Geuken M, Jansen PL, Roskams TA. High expression of MDR1, MRP1, and MRP3 in the hepatic progenitor cell compartment and hepatocytes in severe human liver disease. J Pathol. 2003;200(5):553–60. doi:10.1002/path.1379.CrossRefPubMed

15.

Ernest S, Rajaraman S, Megyesi J, Bello-Reuss EN. Expression of MDR1 (multidrug resistance) gene and its protein in normal human kidney. Nephron. 1997;77(3):284–9.CrossRefPubMed

16.

Marchi N, Hallene KL, Kight KM, Cucullo L, Moddel G, et al. Significance of MDR1 and multiple drug resistance in refractory human epileptic brain. BMC Med. 2004;2:37. doi:10.1186/1741-7015-2-37.CrossRefPubMedPubMedCentral

17.

Enokida H, Shiina H, Igawa M, Ogishima T, Kawakami T, et al. CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer. Cancer Res. 2004;64(17):5956–62. doi:10.1158/0008-5472.CAN-04-0081.CrossRefPubMed

18.

Schaich M, Ritter M, Illmer T, Lisske P, Thiede C, et al. Mutations in ras proto-oncogenes are associated with lower mdr1 gene expression in adult acute myeloid leukaemia. Br J Haematol. 2001;112(2):300–7.CrossRefPubMed

19.

Batetta B, Mulas MF, Petruzzo P, Putzolu M, Bonatesta RR, et al. Opposite pattern of MDR1 and caveolin-1 gene expression in human atherosclerotic lesions and proliferating human smooth muscle cells. Cell Mol Life Sci. 2001;58(8):1113–20.CrossRefPubMed

20.

Jamroziak K, Mlynarski W, Balcerczak E, Mistygacz M, Trelinska J, et al. Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol. 2004;72(5):314–21. doi:10.1111/j.1600-0609.2004.00228.x.CrossRefPubMed

21.

Kurzawski M, Drozdzik M, Suchy J, Kurzawski G, Bialecka M, et al. Polymorphism in the P-glycoprotein drug transporter MDR1 gene in colon cancer patients. Eur J Clin Pharmacol. 2005;61(5-6):389–94. doi:10.1007/s00228-005-0926-5.CrossRefPubMed

22.

Leonessa F, Clarke R. ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer. 2003;10(1):43–73.CrossRefPubMed

23.

Sohn JW, Lee SY, Lee SJ, Kim EJ, Cha SI, et al. MDR1 polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer. Jpn J Clin Oncol. 2006;36(3):137–41. doi:10.1093/jjco/hyi231.CrossRefPubMed

24.

Taniguchi S, Mochida Y, Uchiumi T, Tahira T, Hayashi K, et al. Genetic polymorphism at the 5′ regulatory region of multidrug resistance 1 (MDR1) and its association with interindividual variation of expression level in the colon. Mol Cancer Ther. 2003;2(12):1351–9.PubMed

25.

Wu L, Xu X, Shen J, Xie H, Yu S, et al. MDR1 gene polymorphisms and risk of recurrence in patients with hepatocellular carcinoma after liver transplantation. J Surg Oncol. 2007;96(1):62–8. doi:10.1002/jso.20774.CrossRefPubMed

26.

Yu X, Xie H, Wei B, Zhang M, Wang W, et al. Association of MDR1 gene SNPs and haplotypes with the tacrolimus dose requirements in Han Chinese liver transplant recipients. PLoS One. 2011;6(11):e25933. doi:10.1371/journal.pone.0025933.CrossRefPubMedPubMedCentral

27.

Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004;75(1):13–33. doi:10.1016/j.clpt.2003.09.012.CrossRefPubMed

28.

Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: from genomics to mechanism. Oncogene. 2003;22(47):7468–85. doi:10.1038/sj.onc.1206948.CrossRefPubMed

29.

Chen Y-D, Yang F, Feng S-T, et al. A case-control study on the association between genetic polymorphisms of MDR1 and hepatic cell cancer susceptibility. Chin Clin Oncol. 2009;14(12):1007–81.

30.

Fukuda MKY, Hirota T, et al. Genetic polymorphisms of hepatic ABC-transporter in patients with hepatocellular carcinoma. JCT. 2010;1:114–23.CrossRef

31.

Ren YQ, Han JQ, Cao JB, Li SX, Fan GR. Association of MDR1 gene polymorphisms with susceptibility to hepatocellular carcinoma in the Chinese population. Asian Pac J Cancer Prev. 2012;13(11):5451–4.CrossRefPubMed

32.

Gao J. Association of MDR1 gene polymorphisms with the risk of hepatocellular carcinoma in the Chinese Han population. Braz J Med Biol Res. 2013;46(3):311–7.CrossRefPubMedPubMedCentral

33.

Jing Rui DX, Deng W, et al. Correlation between MDR1 polymorphism and primary liver cancer in Guangxi. Chin J Oncol Prev Treat. 2013;5(2):122–5.

34.

Yang D, Zhou F, Wang X, Gao H, Li G, et al. Association analysis between MDR1 gene polymorphisms and risk of hepatocellular carcinoma in Chinese population. Biomarkers. 2013;18(3):236–41. doi:10.3109/1354750X.2013.773079.CrossRefPubMed

35.

Li XF, He HB, Zhu YS, He JK, Ye WW, et al. Association between the c.3751G > a genetic variant of MDR1 and hepatocellular carcinoma risk in a Chinese Han population. Asian Pac J Cancer Prev. 2013;14(9):5361–5.CrossRefPubMed

36.

Wan YY, Wang XW, Hui HX, Wan L. Association between the c.1564A > T genetic polymorphism of the MDR1 gene and hepatocellular carcinoma in Chinese population. Genet Mol Res. 2014;13(3):6820–6. doi:10.4238/2014.August.29.3.CrossRefPubMed

37.

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W65–94.CrossRefPubMed

38.

Gnad F, Baucom A, Mukhyala K, Manning G, Zhang Z. Assessment of computational methods for predicting the effects of missense mutations in human cancers. BMC Genomics. 2013;14 Suppl 3:S7. doi:10.1186/1471-2164-14-S3-S7.PubMedPubMedCentral

39.

Clark MF, Baudouin SV. A systematic review of the quality of genetic association studies in human sepsis. Intensive Care Med. 2006;32(11):1706–12. doi:10.1007/s00134-006-0327-y.CrossRefPubMed

40.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.CrossRefPubMed

41.

DerSimonian R. Combining evidence from clinical trials. Anesth Analg. 1990;70(5):475–6.CrossRefPubMed

42.

Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. BMJ. 2006;333(7568):597–600. doi:10.1136/bmj.333.7568.597.CrossRefPubMedPubMedCentral

43.

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.CrossRefPubMedPubMedCentral

44.

Pagani F, Raponi M, Baralle FE. Synonymous mutations in CFTR exon 12 affect splicing and are not neutral in evolution. Proc Natl Acad Sci U S A. 2005;102(18):6368–72. doi:10.1073/pnas.0502288102.CrossRefPubMedPubMedCentral

45.

Sauna ZE, Kimchi-Sarfaty C. Understanding the contribution of synonymous mutations to human disease. Nat Rev Genet. 2011;12(10):683–91. doi:10.1038/nrg3051.CrossRefPubMed

Title: Genetic polymorphisms of the multidrug resistance 1 gene MDR1 and the risk of hepatocellular carcinoma
Authors: Zhi-Chao Wang
Long-Zi Liu
Xin-Yang Liu
Jin-Jing Hu
Yong-Na Wu
Jie-Yi Shi
Liu-Xiao Yang
Meng Duan
Xiao-Ying Wang
Jian Zhou
Jia Fan
Qiang Gao
Publication date: 01-09-2015
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 9/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-3407-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2015

Expression of FOXP1 in epithelial ovarian cancer (EOC) and its correlation with chemotherapy resistance and prognosis

Overexpression of stathmin is resistant to paclitaxel treatment in patients with non-small cell lung cancer

Erratum to: Thioridazine specifically sensitizes drug-resistant cancer cells through highly increase in apoptosis and P-gp inhibition

Retraction Note to: A translocator protein ligand PK11195 shows antigrowth activity in human choriocarcinoma cells

Current position of TNF-α in melanomagenesis

Functional elucidation of miR-494 in the tumorigenesis of nasopharyngeal carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer